Ad is loading...
JDVPX
Price
$27.27
Change
+$0.21 (+0.78%)
Updated
Nov 22 closing price
VVIAX
Price
$69.72
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

JDVPX vs VVIAX

Header iconJDVPX vs VVIAX Comparison
Open Charts JDVPX vs VVIAXBanner chart's image
JHancock Disciplined Value R2
Price$27.27
Change+$0.21 (+0.78%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
JDVPX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JDVPX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JDVPX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. JDVPX (16.1B). VVIAX pays higher dividends than JDVPX: VVIAX (2.36) vs JDVPX (0.61). JDVPX was incepted earlier than VVIAX: JDVPX (13 years) vs VVIAX (24 years). JDVPX is a more actively managed with annual turnover of: 43.00 vs. VVIAX (10.00). JDVPX has a lower initial minimum investment than VVIAX: JDVPX (0) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. JDVPX (22.62). VVIAX return over 5 years is better than : 53.09 vs. JDVPX (30.52).
JDVPXVVIAXJDVPX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years24 years-
Gain YTD22.22219.672113%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets16.1B184B9%
Annual Yield % from dividends0.612.3626%
Returns for 1 year22.6226.0987%
Returns for 3 years4.9524.7720%
Returns for 5 years30.5253.0957%
Returns for 10 years41.85112.2637%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics